Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ZYUS Life Sciences ( (TSE:ZYUS) ) has provided an update.
ZYUS Life Sciences Corporation has amended a Promissory Note Agreement with an independent director, replacing it with a loan agreement that increases the principal amount to $0.375 million and extends the maturity date to March 28, 2027. The additional proceeds will be used for general working capital, and the loan includes the issuance of 281,250 common share purchase warrants to the lender, subject to TSX Venture Exchange approval. This transaction, classified as a related party transaction, reflects ZYUS’s strategic financial management and commitment to advancing its cannabinoid-based pharmaceutical initiatives.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management. The company is committed to securing intellectual property protection and obtaining regulatory approval for non-opioid-based pharmaceutical solutions, aiming to transform patients’ lives.
YTD Price Performance: -15.38%
Average Trading Volume: 6,447
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$45.11M
For an in-depth examination of ZYUS stock, go to TipRanks’ Stock Analysis page.